Literature DB >> 23832961

Ghrelin requires p53 to stimulate lipid storage in fat and liver.

Begoña Porteiro1, Alberto Díaz-Ruíz, Gloria Martínez, Ana Senra, Anxo Vidal, Manuel Serrano, Oreste Gualillo, Miguel López, María M Malagón, Carlos Diéguez, Rubén Nogueiras.   

Abstract

Ghrelin, a stomach-derived peptide, stimulates feeding behavior and adiposity. For its orexigenic action, ghrelin triggers a central SIRT1/p53/AMPK pathway. The tumor suppressor p53 also plays an important role in white adipose tissue (WAT), where it is up-regulated in the adipocytes of obese mice. It is not known, however, whether p53 has any role in mediating the peripheral action of ghrelin. In the present study, chronic peripheral ghrelin treatment resulted in increased body weight and fat-mass gain in wild-type mice. Correspondingly, mRNA levels of several adipogenic and fat-storage-promoting enzymes were up-regulated in WAT, whereas hepatic triglyceride content and lipogenic enzymes were also increased in wild-type mice following ghrelin treatment. In contrast, mice lacking p53 failed to respond to ghrelin treatment, with their body weight, fat mass, and adipocyte and hepatic metabolism remaining unchanged. Thus, our results show that p53 is necessary for the actions of ghrelin on WAT and liver, leading to changes in expression levels of lipogenic and adipogenic genes, and modifying body weight.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23832961     DOI: 10.1210/en.2013-1176

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  24 in total

1.  Ghrelin promotes hepatic lipogenesis by activation of mTOR-PPARγ signaling pathway.

Authors:  Ziru Li; Geyang Xu; Yan Qin; Chao Zhang; Hong Tang; Yue Yin; Xinxin Xiang; Yin Li; Jing Zhao; Michael Mulholland; Weizhen Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-25       Impact factor: 11.205

Review 2.  Role of abnormal lipid metabolism in development, progression, diagnosis and therapy of pancreatic cancer.

Authors:  Julian Swierczynski; Areta Hebanowska; Tomasz Sledzinski
Journal:  World J Gastroenterol       Date:  2014-03-07       Impact factor: 5.742

Review 3.  Role of cell cycle regulators in adipose tissue and whole body energy homeostasis.

Authors:  I C Lopez-Mejia; J Castillo-Armengol; S Lagarrigue; L Fajas
Journal:  Cell Mol Life Sci       Date:  2017-10-07       Impact factor: 9.261

4.  Role of ghrelin isoforms in the mitigation of hepatic inflammation, mitochondrial dysfunction, and endoplasmic reticulum stress after bariatric surgery in rats.

Authors:  S Ezquerro; S Becerril; C Tuero; L Méndez-Giménez; F Mocha; R Moncada; V Valentí; J A Cienfuegos; V Catalán; J Gómez-Ambrosi; K Piper Hanley; G Frühbeck; A Rodríguez
Journal:  Int J Obes (Lond)       Date:  2019-07-19       Impact factor: 5.095

5.  Role of aquaporin-7 in ghrelin- and GLP-1-induced improvement of pancreatic β-cell function after sleeve gastrectomy in obese rats.

Authors:  L Méndez-Giménez; S Becerril; S P Camões; I V da Silva; C Rodrigues; R Moncada; V Valentí; V Catalán; J Gómez-Ambrosi; J P Miranda; G Soveral; G Frühbeck; A Rodríguez
Journal:  Int J Obes (Lond)       Date:  2017-06-06       Impact factor: 5.095

Review 6.  The role of the p53 tumor suppressor in metabolism and diabetes.

Authors:  Che-Pei Kung; Maureen E Murphy
Journal:  J Endocrinol       Date:  2016-09-09       Impact factor: 4.286

Review 7.  Ghrelin and liver disease.

Authors:  Mar Quiñones; Johan Fernø; Omar Al-Massadi
Journal:  Rev Endocr Metab Disord       Date:  2020-03       Impact factor: 6.514

Review 8.  Calorie restriction and sirtuins revisited.

Authors:  Leonard Guarente
Journal:  Genes Dev       Date:  2013-10-01       Impact factor: 11.361

Review 9.  Structure and physiological actions of ghrelin.

Authors:  Christine Delporte
Journal:  Scientifica (Cairo)       Date:  2013-11-28

10.  A Population Pharmacokinetic Analysis of PF-5190457, a Novel Ghrelin Receptor Inverse Agonist in Healthy Volunteers and in Heavy Alcohol Drinkers.

Authors:  Enoch Cobbina; Mary R Lee; Lorenzo Leggio; Fatemeh Akhlaghi
Journal:  Clin Pharmacokinet       Date:  2020-11-05       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.